Jpmorgan Chase & CO Cure Vac N.V. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.94 - $4.34 $63,886 - $94,308	21,730 Added 30.47%	93,038 $281,000
Q4 2023 Feb 12, 2024	BUY	$3.96 - $6.41 $116,657 - $188,832	29,459 Added 70.39%	71,308 $300,000
Q3 2023 Nov 14, 2023	BUY	$6.5 - $10.77 $207,233 - $343,369	31,882 Added 319.88%	41,849 $285,000
Q2 2023 Aug 11, 2023	BUY	$6.69 - $12.25 $66,679 - $122,095	9,967 New	9,967 $103,000
Q4 2022 Feb 13, 2023	SELL	$5.75 - $8.5 $62,991 - $93,117	-10,955 Reduced 96.32%	418 $3,000
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $948,882 - $1.93 Million	-126,856 Reduced 91.77%	11,373 $90,000
Q2 2022 Aug 11, 2022	BUY	$13.18 - $19.41 $1.52 Million - $2.24 Million	115,412 Added 505.82%	138,229 $1.88 Million
Q1 2022 May 11, 2022	BUY	$14.73 - $35.25 $88,615 - $212,064	6,016 Added 35.81%	22,817 $448,000
Q4 2021 Feb 10, 2022	BUY	$33.72 - $48.22 $205,186 - $293,418	6,085 Added 56.78%	16,801 $576,000
Q3 2021 Nov 12, 2021	BUY	$49.26 - $74.5 $527,870 - $798,342	10,716 New	10,716 $585,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $514M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.